These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24298985)

  • 1. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
    Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
    Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
    Gómez Valbuena I; Alioto D; Serrano Garrote O; Ferrari Piquero JM
    Farm Hosp; 2016 Jan; 40(1):52-4. PubMed ID: 26882834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
    Kneidinger N; Giessen C; von Wulffen W; Milger K; Schramm R; Jäger G; Nitschko H; Striebinger H; Behr J; Neurohr C
    Int J Infect Dis; 2014 Nov; 28():140-2. PubMed ID: 25267276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
    Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
    Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
    Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
    Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R; Mariette C; Alain S; Lupo J; Thiebaut A; Brion JP; Epaulard O; Saint Raymond C; Malvezzi P; Morand P
    Antiviral Res; 2014 Jan; 101():57-61. PubMed ID: 24184983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E; Kallas WM; Fishman JA
    Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leflunomide for cytomegalovirus: bench to bedside.
    Chacko B; John GT
    Transpl Infect Dis; 2012 Apr; 14(2):111-20. PubMed ID: 22093814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.